Pioneering precision medicine

AC Immune is a clinical-stage biopharmaceutical company emerging as a global leader in precision medicine to diagnose, treat and prevent neurodegenerative diseases.

Since AC Immune’s foundation in 2003, our staff has developed pioneering scientific and clinical expertise in the understanding and treatment of neurodegeneration. Our deep knowledge and cutting-edge technology platforms, SupraAntigen® and Morphomer®, are the engines for our diverse pipeline of clinical and preclinical product candidates.

Our experienced management team combines outstanding scientific, clinical, regulatory, financial and corporate development competencies to build on the seminal work of AC Immune’s founders.

The Board of Directors includes leading industry veterans, who oversee and optimize our corporate strategy and execution. We also benefit from working closely with collaboration partners, investors, clinicians and academic researchers.

~150 Employees
CH / US based in Switzerland with a subsidiary in the US
2003 Founded in
2016 listed on NASDAQ

Our History

AC Immune’s “firsts” and partnerships highlight the excellence of our research, cutting-edge product candidates and the power of our technology platforms in the field of neurodegenerative diseases.

First positive cognitive results for an anti-Tau mAb therapy in Alzheimer’s

+

First clinically validated anti-a-syn vaccine acquired

+

First-in-human clinical study of latest diagnostic a-syn PET tracer

+
2021

Anti-TDP-43 antibody shown to mitigate TDP-43 neuropathology in vivo

+
2020

Morphomer® Tau small molecule aggregation inhibitor clinical trial (ACI-3024)

+
2019

Lilly partnership on Morphomer® Tau aggregation inhibitors ($1.86 billion)

+
2018

Clinical data for Tau PET tracer in progressive supranuclear palsy

+
2017

Nasdaq IPO

+
2016

Clinical vaccine trial in Down syndrome (Abeta vaccine)

+

Janssen partnership for Tau vaccine ($509 million)

+
2015

Anti-phospho-Tau vaccine clinical trial in Alzheimer’s

+
2014

Prevention trial in Alzheimer’s disease (crenezumab)

+
2013

Start of clinical development of anti-Abeta vaccine ACI-24

+

Genentech partnership for anti-Tau antibody semorinemab ($418 million)

+
2012

Genentech partnership for anti-Abeta antibody crenezumab ($300 million)

+
2006

AC Immune founded in Lausanne, Switzerland

+
2003

Our teams

Leadership, collaboration and experience accelerate success.

AC Immune Logo | Pioneering Precision Medicine for neurodegenerative diseases
AC Immune Partners | Pioneering Precision Medicine for neurodegenerative diseases

Our
collaboration
partners

AC Immune’s scientific excellence has been validated through our collaborations with industry-leaders such as Genentech, Janssen, Life Molecular Imaging and Lilly.